首页>
外国专利>
SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION FOR TREATMENT OF CONGESTIVE HEART FAILURE
SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION FOR TREATMENT OF CONGESTIVE HEART FAILURE
展开▼
机译:螺内酯和血管紧张素II拮抗剂联合治疗充血性心力衰竭
展开▼
页面导航
摘要
著录项
相似文献
摘要
A combination therapy comprising a therapeutically-effective amount of an epoxy-free spirolactone-type aldosterone receptor antagonist and a therapeutically-effective amount of an angiotensin II receptor antagonist is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred angiotensin II receptor antagonists are those compounds having high potency and bioavailability and which are characterized in having an imidazole or triazole moiety attached to a biphenylmethyl or pyridinyl/phenylmethyl moiety. A preferred epoxy-free spirolactone-type aldosterone receptor antagonist is spironolactone. A preferred combination therapy includes the angiotensin II receptor antagonist 5-[2-[5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-pyridinyl]phenyl-1H-tetrazole and the aldosterone receptor antagonist spironolactone.
展开▼